论文部分内容阅读
目的:探讨莫西沙星联合阿奇霉素治疗支原体肺炎的临床疗效及安全性。方法:采用完全随机分组的原则将40例支原体肺炎患者分为治疗组和对照组,每组20人,两组患者均给予口服阿奇霉素等抗炎药常规治疗,治疗组在以上基础上同时口服莫西沙星,每日2次,400mg/d,两组疗程均为2周。结果:治疗两周后,治疗组的体温恢复速度、肺部湿啰音消失速度、止咳速度和痰培养结果等与对照组相比,差异明显(P<0.05)。治疗组总有效率为90%,对照组总有效率为75%,两组之间差异有统计学意义(P<0.05)。治疗组的药物不良反应率与对照组相比,差异无统计学意义(P>0.05)。结论:莫西沙星与阿奇霉素联合治疗支原体肺炎,比单一使用阿奇霉素的临床疗效更好,可在临床进一步推广使用。
Objective: To investigate the clinical efficacy and safety of moxifloxacin combined with azithromycin in the treatment of mycoplasma pneumonia. Methods: 40 patients with mycoplasmal pneumonia were randomly divided into treatment group and control group, with 20 patients in each group. All patients were given oral conventional azithromycin and other anti-inflammatory drugs. The treatment group was given oral administration of Mo. Cisapotin, 2 times a day, 400mg / d, two courses were 2 weeks. Results: Compared with the control group, the recovery rate of body temperature, the speed of the disappearance of the pulmonary rales, the cough speed and the sputum culture results of the two groups after treatment for two weeks were significantly different (P <0.05). The total effective rate was 90% in the treatment group and 75% in the control group. The difference between the two groups was statistically significant (P <0.05). Adverse drug reaction rate in the treatment group compared with the control group, the difference was not statistically significant (P> 0.05). Conclusion: Moxifloxacin combined with azithromycin in the treatment of mycoplasma pneumonia is better than the single use azithromycin clinical efficacy, and can be further promoted in clinical use.